Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Che-Kai Tsao

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Digital Health|November 20, 2025
Artificial intelligence in oncology: promise, peril, and the future of patient-physician interactionBirpartap S Thind, Che-Kai Tsao
The Prostate|May 12, 2021
Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settingsOliver Sartor, Sreevalsa Appukkuttan, Jeffrey Weiss, et al.
Urologic Oncology|April 20, 2012
The follicle-stimulating hormone receptor: a novel target in genitourinary malignanciesBenjamin A Gartrell, Che-kai Tsao, Matthew D Galsky
Clinical Genitourinary Cancer|June 22, 2025
Do Older Patients With Metastatic Hormone-Sensitive Prostate Cancer Benefit From Triplet or Doublet Therapy? A Network Meta-AnalysisSusu Zhou, Parissa Alerasool, Noriko Kishi, et al.
European Urology|July 16, 2016
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic FeverChe-Kai Tsao, Matthew D Galsky, William K Oh
European Urology|January 18, 2014
Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancerChe-Kai Tsao, Matthew D Galsky, William K Oh
Therapeutic Advances in Urology|June 3, 2014
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancerChe-Kai Tsao, Elena Cutting, Jacob Martin, et al.
Urologic Oncology|March 22, 2016
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?Reza Mehrazin, Che-Kai Tsao, John Sfakianos, et al.
Cells|November 27, 2021
From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell CarcinomaJonathan Anker, Justin Miller, Nicole Taylor, et al.
Cancers|March 28, 2026
The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging OpportunitiesJing Huang, Xin-Hua Zhu, Lloyd C Trotman, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Digital Health|November 20, 2025
Artificial intelligence in oncology: promise, peril, and the future of patient-physician interactionBirpartap S Thind, Che-Kai Tsao
The Prostate|May 12, 2021
Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settingsOliver Sartor, Sreevalsa Appukkuttan, Jeffrey Weiss, et al.
Urologic Oncology|April 20, 2012
The follicle-stimulating hormone receptor: a novel target in genitourinary malignanciesBenjamin A Gartrell, Che-kai Tsao, Matthew D Galsky
Clinical Genitourinary Cancer|June 22, 2025
Do Older Patients With Metastatic Hormone-Sensitive Prostate Cancer Benefit From Triplet or Doublet Therapy? A Network Meta-AnalysisSusu Zhou, Parissa Alerasool, Noriko Kishi, et al.
European Urology|July 16, 2016
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic FeverChe-Kai Tsao, Matthew D Galsky, William K Oh
European Urology|January 18, 2014
Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancerChe-Kai Tsao, Matthew D Galsky, William K Oh
Therapeutic Advances in Urology|June 3, 2014
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancerChe-Kai Tsao, Elena Cutting, Jacob Martin, et al.
Urologic Oncology|March 22, 2016
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?Reza Mehrazin, Che-Kai Tsao, John Sfakianos, et al.
Cells|November 27, 2021
From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell CarcinomaJonathan Anker, Justin Miller, Nicole Taylor, et al.
Cancers|March 28, 2026
The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging OpportunitiesJing Huang, Xin-Hua Zhu, Lloyd C Trotman, et al.
Pageof 8